Novartis has elected not to exercise its option to license Idenix Pharmaceuticals' IDX184, a potential treatment for hepatitis C. Idenix retains worldwide rights to the drug. "As we continue to develop IDX184, we look forward to seeking a partner that will assist us in maximizing the value of this asset," said Jean-Pierre Sommadossi, Ph.D., chairman and chief executive officer of Idenix. Idenix's release | Report